Long-awaited US FDA update on paclitaxel-coated devices - Andrew Holden

Andrew Holden speaks on the US Food and Drug Administration (FDA) letter stating that the risk of mortality associated with #paclitaxel-coated devices to treat peripheral arterial disease (#PAD) is no longer supported based on data and analyses.